Shp2 – A Promising Target for Neurodegenerative Disease Therapies

The increasing prevalence of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s diseases necessitates innovative therapeutic strategies. A recent review from China Medical University, published in Translational Psychiatry, highlights Shp2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) as a potential molecular “checkpoint” for targeting NDs. Shp2, a multi-domain enzyme encoded by the PTPN11 gene, plays critical roles in regulating cell signalling pathways associated with neuroprotection, synaptic plasticity, and inflammation.

Shp2’s Dual Role in Neurodegeneration

One of the most interesting findings is Shp2’s dual regulatory role. It can promote or inhibit pathways depending on the context, making it a critical player in maintaining neuronal health. For example, in Alzheimer’s disease (AD), Shp2 interacts with tau protein and amyloid precursor protein (APP) to modulate their phosphorylation states, influencing tau tangle formation and amyloid-beta accumulation. In Parkinson’s disease (PD), Shp2 supports mitophagy by activating Parkin, reducing mitochondrial dysfunction—a key feature of PD pathology.

Lead author Dr. Jiao Pang notes, “Shp2’s bidirectional effects make it both a challenge and an opportunity. By understanding these dynamics, we may uncover novel ways to intervene in disease progression.”

Targeting Shp2 for Therapy

Several studies have demonstrated the therapeutic potential of modulating Shp2 activity:

• Alzheimer’s Disease: Shp2 inhibitors reduced amyloid-beta levels and inflammation by modulating the JAK/STAT pathway and autophagy-related processes.

• Parkinson’s Disease: Activators like lovastatin enhanced Shp2-mediated mitophagy, protecting dopaminergic neurons.

• Epilepsy and Multiple Sclerosis: Shp2 regulated synaptic activity and inflammation, offering potential avenues for improving neuronal signalling and reducing neuroinflammatory damage.

Broader Implications for Neurodegenerative Diseases

Shp2’s involvement in various pathogenic factors—oxidative stress, mitochondrial dysfunction, excitotoxicity, and neuroinflammation—highlights its role in neurodegenerative disease pathology. Its ability to regulate multiple signalling pathways, such as Ras/ERK and PI3K/Akt, positions it as a promising therapeutic target.

On the other hand, the complexity of Shp2’s dual functions necessitates a precise approach to therapy. Future research focusing on tissue-specific modulation of Shp2 activity could pave the way for tailored treatments, offering hope for patients with debilitating neurodegenerative diseases.